Advances in the Drug Discovery and Development Pipeline and Emerging Drug Targets

Tuberculosis (TB) remains a critical global health challenge, disproportionately affecting populations in resource-limited settings and vulnerable groups such as children, pregnant individuals, and people living with human immunodeficiency virus (HIV). Despite significant progress in TB treatment and drug development, challenges, including antimicrobial resistance, drug-drug interaction, toxicity, and limited data in special populations, persist. This work explores the transformative advancements in TB therapeutics and the strategic priorities for improving outcomes, overcoming emerging resistance, and ameliorating tolerability.